AN2 Therapeutics (AN2 Therapeutics) Growth Rank : 0 (As of Jun. 10, 2024)

View and export this data going back to 2022. Start your Free Trial

What is AN2 Therapeutics Growth Rank?

AN2 Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

AN2 Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of AN2 Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

AN2 Therapeutics (AN2 Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AN2 Therapeutics Inc (NAS:ANTX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1800 El Camino Real, Suite D, Menlo Park, CA, USA, 94027

Website

https://www.an2therapeutics.com

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Executives

Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
Kabeer Aziz	director	376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211
Adjuvant Global Health Technology Fund De, L.p.	10 percent owner	C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Robin Shane Readnour	director	3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215
Kevin Michael Krause	officer: Chief Strategy Officer	369 27TH STREET, SAN FRANCISCO CA 94131
Eric Easom	director, officer: Chief Executive Officer	171 FOREST LN., MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Joshua M Eizen	officer: See Remarks	3023 MONTBRETIA WAY, SAN RAMON CA 94582
Margaret M Fitzpatrick	director	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Ra Capital Nexus Fund Ii, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Melvin K Spigelman	director	THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Sanjay Chanda	officer: Chief Development Officer	C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Adjuvant Global Health Technology Fund, L.p.	10 percent owner	C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Michael Adrian Nazak	officer: Chief Accounting Officer	5941 OPTICAL COURT, SAN JOSE CA 95138
Lucy Day	officer: Chief Financial Officer	2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301